Wockhardt Group has set up its first facility in Middle East for manufacturing of NCEs (New Chemical Entities) catering to the global
markets through its Dubai arm of its subsidiary Wockhardt Bio AG.
With an aim to grow and further establish their international presence in pharmaceutical manufacturing, Wockhardt inaugurated a 'state-of-the-art' manufacturing facility for the production and packaging of sterile dry powder injection in Dubai. On approval of the new drug by US FDA, this manufacturing facility will be commissioned for commercial production.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
